MOEXIPRIL DOES NOT ALTER THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN

The potential effect of moexipril, a new converting enzyme inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of warfa rin has been investigated. Ten healthy male volunteers received in a r andomised crossover fashion a single oral dose of 50 mg warfarin sodiu m alone and together with the first dose of 6 days of oral treatment w ith moexipril 15 mg o. d. Mean oral plasma clearance of (R)-warfarin w as 175 ml . h-1 in the absence and 181 ml . h-1 in the presence of moe xipril, and the corresponding values for (S)-warfarin were 248 ml . h- 1 and 249 ml . h-1. Apparent volume of distribution, peak plasma conce ntration, time to reach peak concentration and area under the plasma c oncentration-time curve both of (R)- and (S)-warfarin were not signifi cantly affected. Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexi pril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve. The results suggest that a clinica lly important interaction between moexipril and warfarin is unlikely t o occur in patients treated with both drugs.